&w=3840&q=100)
Sun Pharma share slips 2% as USFDA flags 8 observations for Halol facility
Sun Pharma shares dropped in trade after the company announced that United States Food and Drug Administration (USFDA) has issued a Form-483, with 8 observations for its Halol facility in Gujarat.
SI Reporter New Delhi
Sun Pharma share price: India's largest drug maker Sun Pharma shares fell up to 1.99 per cent to hit an intraday low of ₹1,655.05 per share on Monday, June 16, 2025.
At 9:46 AM, Sun Pharma shares were off day's low but continued to trade 0.33 per cent lower at ₹1,683.15 per share. In comparison, BSE Sensex was trading 0.19 per cent higher at 81,275.77 levels.
Why did Sun Pharma shares drop in trade today?
Sun Pharma shares dropped in trade after the company announced that United States Food and Drug Administration (USFDA) has issued a Form-483, with 8 observations for its Halol facility in Gujarat.
USFDA had conducted a Good Manufacturing Practices (GMP) inspection at Halol facility from June 2 to June 13, 2025, the pharmaceutical company said, in a statement.
In an exchange filing, Sun Pharma said, 'We hereby inform you that the USFDA conducted a Good Manufacturing Practices (GMP) inspection of Sun Pharmaceutical Industries Limited's Halol facility (Gujarat, India) from June 2 to June 13, 2025. At the conclusion of the inspection, the US FDA issued a Form-483, with 8 observations.'
Sun Pharma results
Sun Pharma reported a 19 per cent year-on-year decline in consolidated net profit for Q4FY25, coming in at ₹2,149.8 crore. However, revenue from operations rose 8 per cent to ₹12,958.8 crore for the quarter.
Excluding exceptional items, adjusted net profit stood at ₹2,889.1 crore, marking a 4.8 per cent increase.
The company cited seasonally softer sales in the US during January and February as a partial reason for the muted quarterly performance, though it noted that prescription and inventory trends for key brands remained robust. Higher input costs also weighed on profitability.
For the full financial year FY25, net profit grew 14 per cent Y-o-Y to ₹10,929 crore, while revenue increased 8 per cent to ₹52,578 crore.
Despite the annual growth, both Q4 net profit and revenue missed Bloomberg estimates by 23 per cent and 2.23 per cent, respectively.
About Sun Pharma
Established in 1983, Sun Pharmaceutical Industries (Sun Pharma) is the world's fourth-largest specialty generic pharmaceutical company, with global revenues of $5.8 billion. With a presence in over 100 countries and 41 manufacturing facilities worldwide, Sun Pharma delivers high-quality, affordable medicines trusted by healthcare professionals and patients alike.
Its diverse portfolio includes over 2,000 high-quality molecules across generics, branded generics, specialty and complex products, OTC, ARVs, APIs, and intermediates—spanning multiple dosage forms such as tablets, capsules, injectables, inhalers, and topical formulations.
The company is ranked among the top generic pharmaceutical firms in the US, especially in the dermatology space, and maintains a strong presence across key emerging markets like Brazil, Mexico, Russia, and South Africa.
The company consistently invests 6–8 per cent of its global revenues in R&D, supported by a team of over 3,000 scientists, driving innovation in areas like liposomal formulations, lyophilised injections, and controlled-release systems
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
2 hours ago
- Business Standard
Subros zooms 18%, sharpest intra-day rally in 1 year; up 26% in 3 days
Share price of Subros today Shares of Subros hit an all-time high of ₹982.35, zooming 18 per cent thus also recording its sharpest intra-day rally in the past one year, on the BSE in Monday's intra-day deals. Earlier, on July 1, 2024, the stock price of the smallcap company had zoomed 20 per cent in intra-day trades, BSE data shows. In the past three days, the market price of Subros has appreciated by 26 per cent, while, thus far in the month of June, it has gained 35 per cent. It has nearly-doubled or zoomed 96 per cent from its March 2025 low of ₹501.55 on the BSE. At 02:42 PM; Subros was quoting 17 per cent higher at ₹970.70, as compared to 0.84 per cent rise in the BSE Sensex. The average trading volumes at the counter jumped over six-fold. A combined 4.5 million shares representing nearly 7 per cent of total equity of Subros changed hands on the NSE and BSE. Subros clarifies on increase in volume Subros on June 10, 2025, said that the company has made all the necessary disclosures (including unpublished price sensitive information) to the Stock Exchange(s). The significant increase in volume of company's equity shares is purely market driven. 'There is no information/announcement (including impending announcement) which in our opinion may have a bearing on the price/volume behaviour in the scrip and which is due to be disseminated to the Stock Exchange(s),' Subros said. Subros Q4 results For the January to March 2025 quarter (Q4FY25), Subros' revenue was higher by 9.25 per cent year-on-year (YoY) at ₹908.46 crore from corresponding quarter of last year due to increase in volume and Start of Production (SOP) of new business awards. EBIDTA was higher by 22.72 per cent in Q4 from corresponding quarter of last year due to Cost cutting initiatives and process cost optimization. MSR was lower due to softening in commodity prices, cost down initiatives and product mix. Finance cost was lower due to use of low-cost debt instrument and working capital optimization. Growth outlook for Subros Subors medium-term growth prospects remains healthy, given its strong market position in the passenger vehicle (PV) industry and continued demand in the industry. Further, the notification from the Government of India mandating air-conditioned (AC) fitted cabins in N2 and N3 trucks (both segments combined cover trucks having gross vehicle weight exceeding 3.5 tonnes), manufactured after October 2025, is expected to generate incremental revenue prospects for the company. While the company has significantly muted its sales in the home AC segment due to low segment margins amid inflationary pressure in the fixed price nature of contracts, an increase in the contribution from the other business segments, such as commercial vehicle (CVs) and Indian Railways is expected to support its earnings growth prospects, according to ICRA. The ratings for Subros continue to factor in its strong market position in the thermal products segment of the PV industry, benefitting from its integrated manufacturing operations and strong product development capabilities, which is supported by technical support from Denso Corporation, Japan. The company is expected to continue its growth momentum on account of new product development for various models of PVs, buses, trucks and the railways segment, the rating agency said in its rationale. The operating margins and return indicators are expected to improve over the medium term, aided by operational efficiencies, cost efficiency measures as well as increased localisation. About Subros Subros is the leading manufacturer of thermal products for automotive applications in India, in technical collaboration with Denso Corporation, Japan. The company is engaged primarily in the business of manufacturing and sale of thermal products for automotive and home air-conditioning original equipment manufacturers. The company is a joint venture with 36.79 per cent ownership by the Suri family of India, 20 per cent ownership by Denso Corporation, Japan & 11.96 per cent ownership by Suzuki Motor Corporation, Japan.
The Hindu
2 hours ago
- The Hindu
Rupee rises 8 paise to close at 86.03 against U.S. dollar
The rupee rose 8 paise to 86.03 (provisional) against the U.S. dollar on Monday (June 16, 2025) amid a strong show at the domestic equity markets, weakening dollar, and easing of global crude oil prices. However, decline in exports, along with foreign fund outflows, capped further gains in the local unit, forex traders said. At the interbank foreign exchange, the local unit opened at 86.16 against the greenback and traded in the range of 85.94-86.24 before closing at 86.03 (provisional), up 8 paise from its previous close. The rupee had plummeted 59 paise to 86.11 against the U.S. dollar on Friday (June 13, 2025). The rupee regained, 'but there was good dollar buying at lower levels as markets awaited the outcome of the continuing Iran-Israel war in the Middle East', Anil Kumar Bhansali, Head of Treasury and Executive Director, Finrex Treasury Advisors LLP, said, adding that the rupee level could be in a wider range of 85.75 to 86.50 on Tuesday (June 17, 2025). India's exports declined 2.17% to $38.73 billion in May, while the trade deficit stood at $21.88 billion in the month, the latest government data showed on Monday (June 16, 2025). Imports declined 1.7% year-on-year to $60.61 billion in May. Wholesale price inflation (WPI) in the country declined to 0.39% in May as prices of food articles, manufactured products, and fuel eased, as per government data. WPI-based inflation was 0.85% in April. It was 2.74% in May last year. Meanwhile, in the domestic equity market, the 30-share BSE Sensex jumped 677.55 points to settle at 81,796.15 while Nifty climbed 227.90 points to 24,946.50. The prices of Brent crude — the global oil benchmark — dipped 0.79% to 73.64 per barrel in futures trade after rising sharply over the past few days owing to the escalating Israel-Iran conflict. The dollar index, which gauges the greenback's strength against a basket of six currencies, declined 0.20% to 97.98. India's forex reserves increased $5.17 billion to $696.65 billion for the week ended June 6, the Reserve Bank of India said on Friday (June 13, 2025). Foreign institutional investors (FIIs) offloaded equities worth ₹1,263.52 crore on a net basis on Friday (June 13, 2025), according to exchange data.
The Hindu
3 hours ago
- The Hindu
Sensex, Nifty rebound nearly 1% on value buying, global rally
Benchmark stock indices Sensex and Nifty rebounded by nearly 1% on Monday (June 16, 2025), following value buying in IT and oil shares and a rally in global shares amid a drop in Brent crude oil prices. The 30-share BSE Sensex jumped 677.55 points or 0.84%, to settle at 81,796.15. During the day, it surged 747.22 points or 0.92% to 81,865.82. The 50-share NSE Nifty climbed 227.90 points or 0.92% to 24,946.50. Among 30 Sensex firms, UltraTech Cement, Tech Mahindra, HCL Tech, Tata Consultancy Services, Eternal, Asian Paints, Tata Steel and Kotak Mahindra Bank were among the biggest gainers. Tata Motors, Adani Ports and Sun Pharma were the laggards. In Asian markets, South Korea's Kospi, Japan's Nikkei 225 index, Shanghai's SSE Composite index and Hong Kong's Hang Seng settled in the positive territory. European markets were quoting in the green. U.S. markets ended lower on Friday (June 13, 2025). Global oil benchmark Brent crude declined 0.81% to $73.63 a barrel. Wholesale price inflation (WPI) declined to a 14-month low of 0.39% in May on easing prices of food articles and fuel. 'Despite mounting global uncertainty triggered by escalating tensions in the Middle East, Indian markets remained resilient,' Sundar Kewat, Technical and Derivatives Analyst, Ashika Institutional Equity — Ashika Stock Broking part of Ashika Group, said. Foreign Institutional Investors (FIIs) offloaded equities worth ₹1,263.52 crore on Friday (June 13, 2025), according to exchange data. On Friday (June 13, 2025), the 30-share BSE Sensex dived 573.38 points or 0.70% to settle at 81,118.60. The Nifty dropped 169.60 points or 0.68% to 24,718.60. In the past two days, the BSE benchmark has lost 1,396.54 points or 1.69%, and the Nifty dropped 422.8 points or 1.68%.
